X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Expansion of Antitumor Natural Killer Cells Using Anti-CD16 Antibody and Irradiated Autologous Peripheral Blood Mononuclear Cells

Yuvraj_pawp by Yuvraj_pawp
20th November 2017
in Europe, News

Natural killer (NK) cells are lymphocytes of the innate immune system and are important in controlling tumors and infections without depending on the recognition of specific antigens. The activation of NK cells occur via NK cell receptor interactions, including the CD 16 (Fc-gamma) receptors that bind antibodies (eg. IgG) attached to pathogens and infected cells. The CD16 receptor is involved in antibody-dependent cellular cytotoxicity, a process associated with the effectiveness of antibody-based cancer immunotherapies.

CD16 can induce NK cell activation without additional receptor signals; therefore, it can be used as a strategy to promote NK cell expansion. Various cytokines have been used to expand NK cells but without adequate effectiveness. Cancer cells lines have been used as feeder cells (used to nourish cultured tissue cells) for the large-scale expansion of NK cells. However, this requires methods to limit the growth of the feeder cells so that these do not contaminate the expanded NK cells.

To circumvent this issue, researchers instead used irradiated autologous peripheral blood mononuclear cells for large-scale expansion of purified cytotoxic NK cells activated with anti-CD16 monoclonal antibody. They exposed peripheral blood mononuclear cells to a radiation dose sufficient to inactivate T cells during NK expansion. The irradiated donor cells were then cultured with anti-CD16 antibody. This combination induced a stronger increase in expanded NK cells compared to irradiated cells alone. Further, flow cytometry analysis showed that the anti-CD16 and irradiated cell combination upregulated NK cell-activating receptors.

NK cells expanded via the combination method were found to secrete the cytokine INF-gamma after stimulation with target cancer cells (human cancer cell lines). Further, coculturing of target cancer cells with expanded NK cells led to increased target cell death. Tumor growth was suppressed in immunodeficient mice inoculated with lung and colon cancer cells after injection with NK cells expanded by the combination method. The results of these experiments demonstrate that NK cell expansion using anti-CD16 antibody and irradiated peripheral blood mononuclear cells can provide sufficient expansion of purified cytotoxic human NK cells with strong in vitro and in vivo antitumor activity and applicability to antitumor immunotherapy.

Lee, H., Son, C., Koh, E., Bae, J., Kang, C., Yang, K., & Park, Y. (2017). Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Scientific Reports, 7(1). doi:10.1038/s41598-017-09259-1

Previous Post

Sobi begins phase 3 study evaluating safety and efficacy of anakinra to treat Still’s disease

Next Post

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda in Europe

Related Posts

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Next Post

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda in Europe

Latest News

Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In